Last checked at 
(Adds reaction, market reaction)
By Michael Erman and Julie Steenhuysen
Nov 9 (Reuters) - Pfizer Inc said on Monday its
experimental COVID-19 vaccine was more than 90% effective, a
major victory in the fight against a pandemic that has killed
more than a million people, battered the world's economy and
upended daily life.
Pfizer and German partner BioNTech SE are the first
drugmakers to release successful data from a large-scale
clinical trial of a coronavirus vaccine. The companies said they
have so far found no serious safety concerns and expect to seek
U.S. authorization this month for emergency use of the vaccine.
If authorized, the number of doses will initially be limited
and many questions remain, including how long the vaccine will
provide protection. However, the news provides hope that other
COVID-19 vaccines in development may also prove effective.
"Today is a great day for science and humanity," Albert
Bourla, Pfizer's chairman and chief executive, said.
"We are reaching this critical milestone in our vaccine
development program at a time when the world needs it most with
infection rates setting new records, hospitals nearing
over-capacity and economies struggling to reopen."
Pfizer expects to seek broad U.S. authorization for
emergency use of the vaccine for people aged 16 to 85. To do so,
it will need two months of safety data from about half the
study's 44,000 participants, which his expected late this month.
The MSCI index of world stock markets hit a record high
following the announcement. Pfizer shares were indicated 6%
higher in New York, while BioNTech's U.S. stock leapt 18%.
Shares of other COVID-19 vaccine developers that are in the
final stage of testing also reacted with AstraZeneca
rising 0.5% in London while Johnson & Johnson gained
2.6% in pre-market trading and Moderna down 1.8% ahead
of the U.S. bell.
"I'm near ecstatic," Bill Gruber, one of Pfizer's top
vaccine scientists, said in an interview. "This is a great day
for public health and for the potential to get us all out of the
circumstances we're now in."
1.3 BILLION DOSES
Pfizer and BioNTech have a $1.95 billion contract with the
U.S. government to deliver 100 million vaccine doses beginning
this year. They have also reached supply agreements with the
European Union, the United Kingdom, Canada and Japan.
To save time, the companies began manufacturing the vaccine
before they knew whether it would be effective. They now expect
to produce up to 50 million doses, or enough to protect 25
million people this year.
Pfizer said it expects to produce up to 1.3 billion doses of
the vaccine in 2021.
The U.S. pharmaceutical giant said the interim analysis was
conducted after 94 participants in the trial developed COVID-19,
examining how many of them had received the vaccine versus a
placebo.
The company did not break down exactly how many of those who
fell ill received the vaccine. Still, over 90% effectiveness
implies that no more than 8 of the 94 people who caught COVID-19
had been given the vaccine, which was administered in two shots
about three weeks apart.
The efficacy rate is well above the 50% effectiveness
required by the U.S. Food and Drug Administration for a
coronavirus vaccine.
To confirm the efficacy rate, Pfizer said it would continue
the trial until there are 164 COVID-19 cases among participants.
Given the recent spike in U.S. infection rates, that number
could be reached by early December, Gruber said.
The data have yet to be peer-reviewed or published in a
medical journal. Pfizer said it would do so once it has results
from the entire trial.
GLOBAL RACE
The global race for a vaccine has seen wealthier countries
forge multibillion-dollar supply deals with drugmakers like
Pfizer, AstraZeneca Plc and Johnson & Johnson, raising questions
over when middle income and poorer nations will get access to
inoculations.
The U.S. quest for a vaccine has been the Trump
administration's central response to the pandemic. The United
States has the world's highest known number of COVID-19 cases
and deaths with more than 10 million infections and over 237,000
fatalities.
President Donald Trump repeatedly assured the public that
his administration would likely identify a successful vaccine in
time for the presidential election, held last Tuesday. On
Saturday, Democratic rival Joe Biden was declared the winner.
Vaccines are seen as essential tools to help end the health
crisis that has shuttered businesses and left millions out of
work. Millions of children whose schools were closed in March
remain in remote learning programs.
Dozens of drugmakers and research groups around the globe
have been racing to develop vaccines against COVID-19, which on
Sunday exceeded 50 million infections since the new coronavirus
first emerged late last year in China.
The Pfizer and BioNTech vaccine uses messenger RNA (mRNA)
technology, which relies on synthetic genes that can be
generated and manufactured in weeks, and produced at scale more
rapidly than conventional vaccines.
Moderna Inc, whose vaccine candidate employs similar
technology, is expected to report results from its large-scale
trial later this month.
The mRNA technology is designed to trigger an immune
response without using pathogens, such as actual virus
particles.
Pfizer alone will not have the capacity to immediately
provide enough vaccines for the United States. The Trump
administration has said it will have enough supply for all of
the 330 million U.S. residents who wish to be vaccinated by the
middle of 2021.
The U.S. government has said the vaccines will be provided
free to Americans, including the insured, uninsured and those in
government health programs such as Medicare.
(Reporting by Michael Erman and Julie Steenhuysen; Additional
reporting by Michele Gershberg; Editing by Bill Berkrot,
Caroline Humer, Edwina Gibbs and David Clarke)
